Septerna (SEPN) Competitors $23.34 +0.04 (+0.17%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SEPN vs. ACAD, NAMS, LNTH, VKTX, TLX, ADMA, AMRX, APLS, CNTA, and XENEShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include ACADIA Pharmaceuticals (ACAD), NewAmsterdam Pharma (NAMS), Lantheus (LNTH), Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), ADMA Biologics (ADMA), Amneal Pharmaceuticals (AMRX), Apellis Pharmaceuticals (APLS), Centessa Pharmaceuticals (CNTA), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Its Competitors ACADIA Pharmaceuticals NewAmsterdam Pharma Lantheus Viking Therapeutics Telix Pharmaceuticals ADMA Biologics Amneal Pharmaceuticals Apellis Pharmaceuticals Centessa Pharmaceuticals Xenon Pharmaceuticals Septerna (NASDAQ:SEPN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Is SEPN or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Septerna's net margin of -12,053.03%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Septerna's return on equity.Company Net Margins Return on Equity Return on Assets Septerna-12,053.03% -31.52% -23.65% ACADIA Pharmaceuticals 21.80%14.69%9.41% Do analysts prefer SEPN or ACAD? Septerna presently has a consensus target price of $26.75, indicating a potential upside of 14.61%. ACADIA Pharmaceuticals has a consensus target price of $29.12, indicating a potential upside of 38.91%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 Do institutionals and insiders believe in SEPN or ACAD? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings and valuation, SEPN or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$1.08M963.42-$71.80M-$10.09-2.31ACADIA Pharmaceuticals$957.80M3.69$226.45M$1.3315.76 Does the media favor SEPN or ACAD? In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than Septerna. MarketBeat recorded 13 mentions for ACADIA Pharmaceuticals and 8 mentions for Septerna. Septerna's average media sentiment score of 0.62 beat ACADIA Pharmaceuticals' score of 0.23 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryACADIA Pharmaceuticals beats Septerna on 14 of the 16 factors compared between the two stocks. Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.03B$3.37B$6.04B$10.53BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-2.3022.7884.5127.54Price / Sales963.42267.44513.90198.23Price / CashN/A46.9537.5761.53Price / Book2.4710.4912.286.84Net Income-$71.80M-$52.58M$3.32B$276.59M7 Day Performance3.78%0.26%-0.30%0.64%1 Month Performance61.30%15.09%9.36%8.73%1 Year PerformanceN/A17.56%72.91%35.73% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna1.0259 of 5 stars$23.34+0.2%$26.75+14.6%N/A$1.03B$1.08M-2.30N/ANews CoverageACADACADIA Pharmaceuticals4.5075 of 5 stars$21.52-0.3%$29.12+35.3%+35.8%$3.63B$1.02B16.18510Analyst ForecastNAMSNewAmsterdam Pharma1.9609 of 5 stars$32.08-1.2%$42.00+30.9%+97.6%$3.61B$45.56M-19.804LNTHLantheus4.5678 of 5 stars$52.67-0.1%$85.50+62.3%-50.3%$3.58B$1.53B14.01700Analyst RevisionVKTXViking Therapeutics3.9696 of 5 stars$31.65-1.9%$86.42+173.0%-49.8%$3.58BN/A-20.7920Upcoming EarningsTLXTelix Pharmaceuticals4.2392 of 5 stars$10.02-1.6%$21.00+109.6%N/A$3.39B$516.72M0.00N/ATrending NewsAnalyst RevisionGap UpADMAADMA Biologics3.5092 of 5 stars$14.06-0.1%$27.67+96.8%-8.7%$3.36B$426.45M16.35530AMRXAmneal Pharmaceuticals3.2454 of 5 stars$10.56+0.0%$12.00+13.7%+12.2%$3.32B$2.85B1,056.568,100APLSApellis Pharmaceuticals4.1819 of 5 stars$24.67+1.3%$33.29+35.0%-15.4%$3.12B$754.65M-13.58770Analyst RevisionCNTACentessa Pharmaceuticals2.8403 of 5 stars$23.16+0.7%$32.38+39.8%+34.5%$3.11B$6.85M-12.99200XENEXenon Pharmaceuticals2.4731 of 5 stars$39.05-1.3%$53.30+36.5%-2.8%$3.00B$7.50M-10.97210Analyst Forecast Related Companies and Tools Related Companies ACAD Competitors NAMS Competitors LNTH Competitors VKTX Competitors TLX Competitors ADMA Competitors AMRX Competitors APLS Competitors CNTA Competitors XENE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SEPN) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
